Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1993 Jan 15;90(2):408-12.
doi: 10.1073/pnas.90.2.408.

Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase

N Adham  1 , H T Kao, L E Schecter, J Bard, M Olsen, D Urquhart, M Durkin, P R Hartig, R L Weinshank, T A Branchek
Affiliations

Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase

N Adham et al. Proc Natl Acad Sci U S A. .

Abstract

An intronless gene encoding an additional human serotonin (5-HT) 5-HT1-like receptor subtype was isolated from a human genomic library with probes obtained from degenerate PCR primers used to amplify 5-HT-receptor-specific sequences. The highest degree of homology was found with the 5-HT1E subtype (70%) and the 5-HT1D alpha (63%) and 5-HT1D beta (60%) receptors. RNA for this gene was detected in the human brain but was not detected in kidney, liver, spleen, heart, pancreas, and testes. High-affinity (Kd = 9.2 nM) 3H-labeled 5-HT binding was detected. Competition studies revealed the following rank order of potencies for serotonergic ligands: 5-HT > sumatriptan >> 5-carboxyamidotryptamine > 8-hydroxy-2(di-1-propylamino)tetralin > spiperone. 5-HT produced a dose-dependent inhibition of forskolin-stimulated cAMP accumulation (EC50 = 7.9 nM) in transfected cells. These properties distinguish this receptor from any previously characterized and establish a fifth 5-HT1-like receptor subtype (5-HT1F) coupled to the inhibition of adenylate cyclase.

PubMed Disclaimer

References

    1. Mol Pharmacol. 1990 Nov;38(5):681-8 - PubMed
    1. Annu Rev Pharmacol Toxicol. 1990;30:307-48 - PubMed
    1. Mol Pharmacol. 1991 Aug;40(2):143-8 - PubMed
    1. EMBO J. 1991 Dec;10(13):4017-23 - PubMed
    1. Mol Pharmacol. 1992 Jan;41(1):1-7 - PubMed

Publication types

MeSH terms

Associated data